Therefore, it should be remembered that CDX2 - CK20 - CRCs can metastasize to the liver.13 Notably, a significant proportion of breast carcinoma (35.7%) and gastric adenocarcinoma (33.3%) cases were CK7- CK20+, which suggests that this finding could be due to changes in the immunoprofile of metastatic tumors or expression loss related to treatment effects. Here, CDX2 is linked to metastatic neoplasm.